GLP-1 insurance coverage: what's covered, what isn't, and prior authorization

'Does insurance cover this?' is the first question most people ask about a GLP-1, and the honest answer is: it depends on which condition you're being treated for, which plan you have, and whether you can clear a prior authorization hurdle. Here's the actual structure behind that answer.

The split that determines everything: diabetes vs. obesity

The single biggest factor in GLP-1 coverage is which FDA-approved indication you're being treated under. Semaglutide and tirzepatide are approved both for type 2 diabetes (as Ozempic and Mounjaro) and for chronic weight management (as Wegovy and Zepbound)³. Historically, health plans have covered the diabetes indication far more consistently than the obesity one — diabetes drugs are treated as standard chronic-disease management, while anti-obesity medications have long been carved out or restricted by many commercial plans, and by Medicare Part D by statute, which has excluded weight-loss drugs from coverage even as the clinical evidence for obesity treatment has grown¹. Survey data backs up how much this matters in practice: a meaningful share of US adults who've used a GLP-1 report doing so despite it being unaffordable, which is largely a coverage-gap story².

Where Medicare and Medicaid stand

Medicare Part D's statutory exclusion of weight-loss medications is the reason many older adults can access a GLP-1 through Medicare only if they qualify under a covered indication like diabetes or, more recently, an added cardiovascular-risk-reduction label rather than obesity alone. Expanding Medicare coverage specifically for obesity has been modeled and debated at the federal level, with real questions about the fiscal impact of doing so at scale¹. Medicaid coverage for anti-obesity medications varies state by state, with some states covering it and others not — there's no single national answer, so the only reliable way to know your state's Medicaid policy is to check directly with your plan or state Medicaid office.

What prior authorization actually checks

When a commercial plan does cover the obesity indication, it almost always gates that coverage behind prior authorization (PA) — a review process where your prescriber submits documentation before the plan will pay. PA criteria commonly include a minimum BMI threshold (often 30, or 27 with a weight-related comorbidity like hypertension or sleep apnea, mirroring the FDA label's own eligibility criteria), documentation of prior weight-management attempts such as a structured diet and exercise program, and sometimes a requirement to try a lower-cost alternative first (step therapy). PA can take anywhere from days to weeks, can be denied and appealed, and commonly needs to be renewed annually. None of this is optional paperwork you can skip by paying a telehealth desk instead — cash-pay providers bypass insurance entirely, which is exactly why so much of this market exists outside the PA process. See compounded vs brand-name GLP-1 for how that trade-off plays out on price.

What to actually check before you assume coverage

Don't take a provider's marketing claim about insurance ('most plans cover this') at face value. Instead: call the number on your insurance card and ask specifically whether your plan covers Wegovy or Zepbound (not just 'semaglutide' or 'tirzepatide' generically, since the brand and indication matter) for the weight-management indication, whether prior authorization is required and what the criteria are, and what your specific copay or coinsurance would be once approved. Ask your prescriber's office whether they handle PA submissions — many telehealth and in-person practices that route to brand-name products will do this for you. If a provider genuinely can't tell you whether they route to insurance-covered brand product, that's a sign they may only be able to offer the cash-pay compounded path.

If you don't have coverage

If your plan excludes the obesity indication outright, or PA is denied and appeals don't work, your options are the manufacturer's cash-pay self-pay program for the brand (still expensive, though sometimes below list price), or a compounded telehealth provider, where our how much does semaglutide cost and how much does tirzepatide cost breakdowns show what the cash market actually looks like. Whichever path you're on, our 5-minute provider checklist covers what to verify beyond the price tag, and every provider's current pricing and access footprint is tracked in our provider briefs. This is coverage and market context, not medical or insurance advice — for anything specific to your plan, your insurer's member services line is the authoritative source.